The recently unveiled conjugate DS3610a is to start phase 1.
ApexOnco Front Page
Recent articles
After menin, the company tries again with farnesyl transferase.
New draft guidance could see the agency getting ever stricter.
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
After Dren secured buy-in from Novartis, LTZ becomes a clinical player.
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
Posters and mini-orals include another VEGF bispecific.
Interius, one of the most advanced players, will cost $350m.
